In this whitepaper, RoosterBio and TAmiRNA jointly demonstrate the power of small RNA-sequencing for robust, high-resolution characterization of exosomes. Umbilical cord, bone marrow, and adipose MSC-derived exosomes produced via RoosterBio’s standardized, xeno-free manufacturing platform in combination with TAmiRNA’s miND® workflow delivers excellent reproducibility across technical replicates and reveals distinct, tissue-specific microRNA signatures. This work highlights the value of omics-based analytics for understanding exosome biology, consistency, and therapeutic potential.

This study was designed to assess both the analytical robustness of TAmiRNA’s miND® small RNA-sequencing workflow and the biological relevance of microRNA cargo profiling as an advanced “omics-based” characterization strategy for therapeutic extracellular vesicles (EVs). It demonstrates that small RNA-sequencing performed with the miND® workflow yields highly reproducible and quantitatively consistent microRNA profiles, confirming the robustness of TAmiRNA’s analytical pipeline and the stability of RoosterBio’s exosome products. In addition, comparative profiling of EVs derived from umbilical cord, bone marrow, and adipose tissue MSCs revealed distinct and tissue-specific microRNA signatures. The results illustrate the value of comprehensive, quantitative RNA profiling as a powerful tool for EV characterization, potency-relevant biomarker discovery, and CMC-aligned analytical development.